CA2616122A1 - Mutants de la cysteine tronques il28 et il29 et procedes antiviraux mettant en oeuvre ceux-ci - Google Patents
Mutants de la cysteine tronques il28 et il29 et procedes antiviraux mettant en oeuvre ceux-ci Download PDFInfo
- Publication number
- CA2616122A1 CA2616122A1 CA002616122A CA2616122A CA2616122A1 CA 2616122 A1 CA2616122 A1 CA 2616122A1 CA 002616122 A CA002616122 A CA 002616122A CA 2616122 A CA2616122 A CA 2616122A CA 2616122 A1 CA2616122 A1 CA 2616122A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- virus
- encoded
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70090505P | 2005-07-20 | 2005-07-20 | |
US60/700,905 | 2005-07-20 | ||
PCT/US2006/028215 WO2007012033A2 (fr) | 2005-07-20 | 2006-07-20 | Mutants de la cysteine tronques il28 et il29 et procedes antiviraux mettant en oeuvre ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2616122A1 true CA2616122A1 (fr) | 2007-01-25 |
Family
ID=37600989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002616122A Abandoned CA2616122A1 (fr) | 2005-07-20 | 2006-07-20 | Mutants de la cysteine tronques il28 et il29 et procedes antiviraux mettant en oeuvre ceux-ci |
Country Status (7)
Country | Link |
---|---|
US (3) | US20070053933A1 (fr) |
EP (1) | EP1912668A2 (fr) |
JP (1) | JP2009502803A (fr) |
AU (1) | AU2006269908A1 (fr) |
CA (1) | CA2616122A1 (fr) |
IL (1) | IL188350A0 (fr) |
WO (1) | WO2007012033A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283448B2 (en) | 2004-04-02 | 2012-10-09 | Zymogenetics, Inc. | Methods for treating viral infection using IL-28 and IL-29 cysteine mutants |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
CA2503305A1 (fr) * | 2002-10-23 | 2004-05-06 | Zymogenetics, Inc. | Procedes de traitement d'infection virale a l'aide de il-28 et il-29 |
EP2251353B1 (fr) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Propositions homogènes de IL-29 |
US20070053933A1 (en) * | 2005-07-20 | 2007-03-08 | Sheppard Paul O | IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME |
EP1909821A2 (fr) * | 2005-07-20 | 2008-04-16 | ZymoGenetics, Inc. | Utilisation de mutants de cysteine d'il28 et d'il29 tronques pour le traitement de cancers et de troubles autoimmuns |
KR20080042174A (ko) * | 2005-10-07 | 2008-05-14 | 화이자 프로덕츠 인코포레이티드 | 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법 |
WO2009149377A1 (fr) | 2008-06-05 | 2009-12-10 | Zymogenetics, Llc | Utilisation d'interferons de type iii pegyles dans le traitement de l'hepatite c |
US20100093618A1 (en) * | 2008-10-15 | 2010-04-15 | Quinto Ileana | Polypeptide capable of inhibiting hiv-1 transcription and replication and uses thereof |
EP2350124A1 (fr) * | 2008-11-20 | 2011-08-03 | Zymogenetics, Inc. | Mutants de il-29 et leurs applications |
US20100316604A1 (en) * | 2009-04-21 | 2010-12-16 | Asterion Limited | Interferon lambda fusion polypeptides |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
CN103923209B (zh) * | 2014-05-13 | 2016-06-22 | 北京凯因科技股份有限公司 | 一种Lambda干扰素突变体及聚乙二醇衍生物 |
CN105085658B (zh) * | 2014-05-14 | 2019-12-24 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体及聚乙二醇衍生物 |
DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
CN112694526B (zh) * | 2020-05-27 | 2023-01-20 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US6468776B1 (en) * | 2000-03-03 | 2002-10-22 | Zymogenetics, Inc. | Human serine protease |
ES2286128T3 (es) * | 2000-06-30 | 2007-12-01 | Zymogenetics, Inc. | Proteina zcyto21 tipo interferon. |
AU2001271589A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
US7038032B2 (en) * | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
CN101676728A (zh) * | 2002-04-19 | 2010-03-24 | 津莫吉尼蒂克斯公司 | 细胞因子受体 |
CA2503305A1 (fr) * | 2002-10-23 | 2004-05-06 | Zymogenetics, Inc. | Procedes de traitement d'infection virale a l'aide de il-28 et il-29 |
EP2251353B1 (fr) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Propositions homogènes de IL-29 |
AU2005231476B2 (en) * | 2004-04-02 | 2011-09-01 | Zymogenetics, Inc. | Il-28 and il-29 cysteine mutants for treating viral infection |
EP1793845A2 (fr) * | 2004-07-29 | 2007-06-13 | ZymoGenetics, Inc. | Utilisation des molecules il-28 et il-29 pour traiter le cancer |
US20070053933A1 (en) * | 2005-07-20 | 2007-03-08 | Sheppard Paul O | IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME |
EP1909821A2 (fr) * | 2005-07-20 | 2008-04-16 | ZymoGenetics, Inc. | Utilisation de mutants de cysteine d'il28 et d'il29 tronques pour le traitement de cancers et de troubles autoimmuns |
ES2357152T3 (es) * | 2005-10-04 | 2011-04-19 | Zymogenetics, L.L.C. | Producción y purificación de il-29. |
-
2006
- 2006-07-20 US US11/458,945 patent/US20070053933A1/en not_active Abandoned
- 2006-07-20 CA CA002616122A patent/CA2616122A1/fr not_active Abandoned
- 2006-07-20 EP EP06787996A patent/EP1912668A2/fr not_active Withdrawn
- 2006-07-20 JP JP2008522960A patent/JP2009502803A/ja active Pending
- 2006-07-20 WO PCT/US2006/028215 patent/WO2007012033A2/fr active Application Filing
- 2006-07-20 AU AU2006269908A patent/AU2006269908A1/en not_active Abandoned
-
2007
- 2007-12-24 IL IL188350A patent/IL188350A0/en unknown
-
2011
- 2011-03-07 US US13/042,083 patent/US20110182852A1/en not_active Abandoned
- 2011-12-20 US US13/331,000 patent/US20120114590A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283448B2 (en) | 2004-04-02 | 2012-10-09 | Zymogenetics, Inc. | Methods for treating viral infection using IL-28 and IL-29 cysteine mutants |
US8816053B2 (en) | 2004-04-02 | 2014-08-26 | Zymogenetics, Inc. | Methods for treating viral infection using IL-28 and IL-29 cysteine mutants |
Also Published As
Publication number | Publication date |
---|---|
WO2007012033A2 (fr) | 2007-01-25 |
US20110182852A1 (en) | 2011-07-28 |
WO2007012033A9 (fr) | 2007-04-05 |
EP1912668A2 (fr) | 2008-04-23 |
WO2007012033A3 (fr) | 2008-04-24 |
IL188350A0 (en) | 2008-04-13 |
JP2009502803A (ja) | 2009-01-29 |
US20070053933A1 (en) | 2007-03-08 |
AU2006269908A1 (en) | 2007-01-25 |
US20120114590A1 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005231476B2 (en) | Il-28 and il-29 cysteine mutants for treating viral infection | |
US20070053933A1 (en) | IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME | |
US8318147B2 (en) | Use of IL-29 for treating a dengue virus infection | |
US8313739B2 (en) | Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |